查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585617

生物工程蛋白药物市场：按药物类型、疾病和最终用户划分 - 全球预测 2025-2030

Bioengineered Protein Drugs Market by Drug Type (Monoclonal Antibodies, Therapeutic Proteins, Vaccines), Disease (Arthritis, Autoimmune Disorders, Blood Disorders), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

生物工程蛋白药物市场2023年估值为3,870.3亿美元，预计到2024年将达到4,151.3亿美元，复合年增长率为7.76%，到2030年将达到6533.5亿美元。

生物工程蛋白质药物，也称为生技药品，是指透过重组DNA技术製造的治疗性蛋白质，对于治疗多种疾病至关重要，包括癌症、糖尿病和自体免疫疾病。他们的需求源自于他们能够高精度地针对特定途径，描述传统小分子药物无法满足的治疗选择。它具有单株抗体、疫苗和荷尔蒙治疗等应用，并具有广泛的最终用途，包括医院、诊所和研究机构。该市场受到多种因素的影响，包括慢性病的流行、基因和蛋白质工程的技术进步以及支持性的政府法规。越来越多的老年人和医疗保健提供者对生技药品认识的提高进一步推动了需求。潜在的机会包括扩展到获得先进治疗方法有限的新兴市场，以及使产品系列多样化以包括个人化医疗方法。生技公司之间的策略联盟增强了研发能力，实现了突破性创新和快速商业化。然而，挑战包括高昂的开发成本、复杂的製造流程、严格的监管要求以及来自生物相似药的竞争。此外，市场成长受到价格压力和专利到期的限制。对于业务成长而言，重点关注药物输送系统和生物加工技术的创新以提高产品功效和患者依从性非常重要。开拓具有成本效益且可靠的生物相似药可以在专利到期后占领市场占有率。此外，在药物开发和患者选择中探索人工智慧和机器学习可以完善治疗应用。该市场的特点是技术快速发展和研发方面的大量投资，凸显了持续创新的需求。公司透过采用资料主导的决策并积极参与策略联盟来确保生物工程蛋白药物领域的持续成长，以保持竞争优势并捕捉新兴市场趋势。

主要市场统计
基准年[2023] 3870.3亿美元
预测年份 [2024] 4151.3亿美元
预测年份 [2030] 6533.5亿美元
复合年增长率（%） 7.76%

市场动态：揭示快速发展的生物工程蛋白质药物市场的关键市场洞察

生物工程蛋白质药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 人口中慢性病盛行率上升
    • 提高医疗意识和生物工程蛋白药物的巨大好处
    • 各国医疗支出增加
  • 市场限制因素
    • 与生物工程蛋白质药物相关的高成本
  • 市场机会
    • 活性化新生物工程蛋白药物的开发与引进研究活动
    • 奈米技术在大分子递送的新应用
  • 市场问题
    • 核准过程艰难且漫长

波特五力：驾驭生物工程蛋白药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解生物工程蛋白药物市场的外部影响

外部宏观环境因素在塑造生物工程蛋白药物市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解生物工程蛋白质药物市场的竞争格局

对生物工程蛋白药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵生物工程蛋白药物市场供应商的绩效评估

FPNV 定位矩阵是评估生物工程蛋白药物市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：在生物工程蛋白药物市场中製定成功之路

对于旨在加强其在全球市场的影响力的公司来说，对生物工程蛋白药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人口中慢性病盛行率不断上升
      • 提高医疗意识和生物工程蛋白药物的巨大好处
      • 各国医疗费用支出增加
    • 抑制因素
      • 与生物工程蛋白质药物相关的高成本
    • 机会
      • 扩大新生物工程蛋白质药物开发与引进的研究活动
      • 奈米技术在大分子递送的新应用
    • 任务
      • 严格而漫长的核准流程
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章生物工程蛋白药物市场：依药物类型

  • 介绍
  • 单株抗体
  • 治疗性蛋白质
  • 疫苗

第七章生物工程蛋白药物市场：依疾病分类

  • 介绍
  • 关节炎
  • 自体免疫疾病
  • 血液疾病
  • 癌症
  • 先天性疾病
  • 心臟病
  • 感染疾病
  • 神经退化性疾病
  • 呼吸系统疾病
  • 皮肤病

第八章生物工程蛋白质药物市场：依最终用户分类

  • 介绍
  • CRO
  • 製药和生物技术公司
  • 研究所

第九章美洲生物工程蛋白药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太生物工程蛋白药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲生物工程蛋白药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Ambrx, Inc.
  • AMGEN INC.
  • Aravive, Inc.
  • Astrazeneca PLC
  • Baxter Healthcare
  • Bayer Pharmaceuticals
  • BRISTOL-MYERS SQUIBB
  • CSL LTD.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • GRIFOLS SA
  • Hoffman-la-Roche
  • MERCK & CO., INC.
  • NOVARTIS AG
  • NOVO NORDISK A/S
  • PFIZER INC.
  • Polaris Group
  • REGENERON PHARMACEUTICALS INC.
  • SANOFI
  • TAKEDA PHARMACEUTICAL CO., LTD.
Product Code: MRR-69324464D0EE

The Bioengineered Protein Drugs Market was valued at USD 387.03 billion in 2023, expected to reach USD 415.13 billion in 2024, and is projected to grow at a CAGR of 7.76%, to USD 653.35 billion by 2030.

Bioengineered protein drugs, also known as biologics, refer to therapeutic proteins created through recombinant DNA technology and are essential for treating various diseases such as cancer, diabetes, and autoimmune disorders. Their necessity stems from their ability to target specific pathways with high precision, offering treatment options where traditional small-molecule drugs fall short. Applications include monoclonal antibodies, vaccines, and hormone treatments, with end-use spanning hospitals, clinics, and research institutions. The market is influenced by several factors, such as increasing prevalence of chronic diseases, technological advancements in genetic and protein engineering, and supportive government regulations. A growing geriatric population and heightened awareness of biologics among healthcare providers further drive demand. Potential opportunities include expanding into emerging markets with limited access to advanced therapeutics and diversifying product portfolios to include personalized medicine approaches. Strategic alliances between biotech firms can enhance R&D capabilities, enabling breakthrough innovations and faster commercialization. However, challenges such as high development costs, complex manufacturing processes, stringent regulatory requirements, and competition from biosimilars pose limitations. Additionally, market growth is constrained by pricing pressures and patent expirations. For business growth, focusing on innovations in drug delivery systems and bioprocessing technologies to improve product efficacy and patient compliance is crucial. Developing biosimilars with cost-effectiveness and reliability can capture market share post-patent expiration. Furthermore, exploring artificial intelligence and machine learning in drug development and patient selection can refine therapeutic applications. The market is characterized by rapid technological evolution and significant investment in research and development, underscoring the need for continuous innovation. Companies should employ data-driven decision-making and actively engage in strategic collaborations to maintain competitive advantage and capture emerging market trends, thereby ensuring sustained growth in the bioengineered protein drugs sector.

KEY MARKET STATISTICS
Base Year [2023] USD 387.03 billion
Estimated Year [2024] USD 415.13 billion
Forecast Year [2030] USD 653.35 billion
CAGR (%) 7.76%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bioengineered Protein Drugs Market

The Bioengineered Protein Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases among population
    • Growing healthcare awareness and significant benefits of bioengineered protein drugs
    • Increase in healthcare spending across economies
  • Market Restraints
    • High costs associated with the bioengineered protein drugs
  • Market Opportunities
    • Growing research activities to develop and introduce novel bioengineered protein drugs
    • Emerging applications of nanotechnology in macromolecules delivery
  • Market Challenges
    • Stringent and time consuming approval processes

Porter's Five Forces: A Strategic Tool for Navigating the Bioengineered Protein Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bioengineered Protein Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bioengineered Protein Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bioengineered Protein Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bioengineered Protein Drugs Market

A detailed market share analysis in the Bioengineered Protein Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bioengineered Protein Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bioengineered Protein Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bioengineered Protein Drugs Market

A strategic analysis of the Bioengineered Protein Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bioengineered Protein Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ambrx, Inc., AMGEN INC., Aravive, Inc., Astrazeneca PLC, Baxter Healthcare, Bayer Pharmaceuticals, BRISTOL-MYERS SQUIBB, CSL LTD., F. HOFFMANN-LA ROCHE AG, GLAXOSMITHKLINE PLC, GRIFOLS S.A., Hoffman-la-Roche, MERCK & CO., INC., NOVARTIS AG, NOVO NORDISK A/S, PFIZER INC., Polaris Group, REGENERON PHARMACEUTICALS INC., SANOFI, and TAKEDA PHARMACEUTICAL CO., LTD..

Market Segmentation & Coverage

This research report categorizes the Bioengineered Protein Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Monoclonal Antibodies, Therapeutic Proteins, and Vaccines.
  • Based on Disease, market is studied across Arthritis, Autoimmune Disorders, Blood Disorders, Cancer, Congenital Diseases, Heart Diseases, Infectious Diseases, Neurodegenerative Diseases, Respiratory Diseases, and Skin Diseases.
  • Based on End-User, market is studied across CROs, Pharmaceutical and Biotechnology Companies, and Research institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases among population
      • 5.1.1.2. Growing healthcare awareness and significant benefits of bioengineered protein drugs
      • 5.1.1.3. Increase in healthcare spending across economies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with the bioengineered protein drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research activities to develop and introduce novel bioengineered protein drugs
      • 5.1.3.2. Emerging applications of nanotechnology in macromolecules delivery
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent and time consuming approval processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bioengineered Protein Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Therapeutic Proteins
  • 6.4. Vaccines

7. Bioengineered Protein Drugs Market, by Disease

  • 7.1. Introduction
  • 7.2. Arthritis
  • 7.3. Autoimmune Disorders
  • 7.4. Blood Disorders
  • 7.5. Cancer
  • 7.6. Congenital Diseases
  • 7.7. Heart Diseases
  • 7.8. Infectious Diseases
  • 7.9. Neurodegenerative Diseases
  • 7.10. Respiratory Diseases
  • 7.11. Skin Diseases

8. Bioengineered Protein Drugs Market, by End-User

  • 8.1. Introduction
  • 8.2. CROs
  • 8.3. Pharmaceutical and Biotechnology Companies
  • 8.4. Research institutes

9. Americas Bioengineered Protein Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bioengineered Protein Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bioengineered Protein Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Ambrx, Inc.
  • 3. AMGEN INC.
  • 4. Aravive, Inc.
  • 5. Astrazeneca PLC
  • 6. Baxter Healthcare
  • 7. Bayer Pharmaceuticals
  • 8. BRISTOL-MYERS SQUIBB
  • 9. CSL LTD.
  • 10. F. HOFFMANN-LA ROCHE AG
  • 11. GLAXOSMITHKLINE PLC
  • 12. GRIFOLS S.A.
  • 13. Hoffman-la-Roche
  • 14. MERCK & CO., INC.
  • 15. NOVARTIS AG
  • 16. NOVO NORDISK A/S
  • 17. PFIZER INC.
  • 18. Polaris Group
  • 19. REGENERON PHARMACEUTICALS INC.
  • 20. SANOFI
  • 21. TAKEDA PHARMACEUTICAL CO., LTD.

LIST OF FIGURES

  • FIGURE 1. BIOENGINEERED PROTEIN DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOENGINEERED PROTEIN DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOENGINEERED PROTEIN DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CONGENITAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEART DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SKIN DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CROS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 61. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 64. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 70. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 73. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 85. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 95. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 101. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 107. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 110. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 113. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 116. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 122. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 125. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 131. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 137. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 143. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 146. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 154. BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023